These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 4293687)

  • 1. A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine.
    Vonka V; Janda Z; Simon J; Adam E; Stárek M
    Prog Med Virol; 1967; 9():204-55. PubMed ID: 4293687
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies of genetic markers of poliovirus strains].
    Yamawaki S
    Kumamoto Igakkai Zasshi; 1970 Dec; 44(12):1165-208. PubMed ID: 4325315
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus.
    Bull World Health Organ; 1969; 40(6):925-45. PubMed ID: 4310724
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation of type 3 poliovirus variants with increased L-cystine-dependence as live vaccines.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV; Sokolova IS; Alpatova GA
    Arch Gesamte Virusforsch; 1971; 33(3):259-70. PubMed ID: 4329636
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poliomyelitis associated with type-2 poliovirus vaccine strain. Possible transmission from an immunised child to a non-immunised child.
    Stolley PD; Joseph JM; Allen JC; Deane G; Janney JH
    Lancet; 1968 Mar; 1(7544):661-3. PubMed ID: 4170650
    [No Abstract]   [Full Text] [Related]  

  • 7. Evolution and polymorphism of poliovirus genomes.
    Crainic R; Kew O
    Biologicals; 1993 Dec; 21(4):379-84. PubMed ID: 8024754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the neutralization of poliovirus by fecal immunoglobulins. The development of intestinal IgA antibodies following oral poliovirus immunization.
    Keller R; Dwyer JE
    Prog Immunobiol Stand; 1970; 4():316-22. PubMed ID: 4320518
    [No Abstract]   [Full Text] [Related]  

  • 9. Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis.
    Racaniello VR; Ren R; Bouchard M
    Dev Biol Stand; 1993; 78():109-16. PubMed ID: 8388820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
    Böttiger M
    Arch Gesamte Virusforsch; 1971; 35(2):251-5. PubMed ID: 4332939
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunization with inactivated poliovirus vaccine and attenuated type 3 poliovirus. II. Parallel vaccinations and cross-wise revaccination in school children with the Sabin and WM3 attenuated strains.
    Böttiger M
    J Pediatr; 1969 Aug; 75(2):273-80. PubMed ID: 4307564
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vaccine (OPV): regulatory aspects.
    Fenyves A
    Dev Biol Stand; 1993; 78():157-9. PubMed ID: 8388826
    [No Abstract]   [Full Text] [Related]  

  • 13. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
    J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
    Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
    Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on characteristics of poliovirus. 3. Investigation of d, rct, h and n markers of poliovirus isolated after vaccination with the Type 1, Chat strain.
    Böttiger M
    Arch Gesamte Virusforsch; 1966; 18(2):135-54. PubMed ID: 4293025
    [No Abstract]   [Full Text] [Related]  

  • 17. Diplovax. A new oral polio vaccine.
    Med Lett Drugs Ther; 1972 Aug; 14(16):57-8. PubMed ID: 4346222
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poliovirus-sensitive transgenic mice as a new animal model.
    Koike S; Horie H; Sato Y; Ise I; Taya C; Nomura T; Yoshioka I; Yonekawa H; Nomoto A
    Dev Biol Stand; 1993; 78():101-7. PubMed ID: 8388819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation and reversion of the Sabin vaccine strains of poliovirus.
    Minor PD
    Dev Biol Stand; 1993; 78():17-26. PubMed ID: 8388828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.